Targeted therapies in lung cancer

Surgical Pathology Clinics

Volumn 3, Issue 1, 2010, Pages 71-82

  Chirieac, Lucian R ^a   Dacic, Sanja ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Lung cancer; Molecular pathogenesis; Squamous; Tyrosine kinase inhibitors

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CANERTINIB; CEDIRANIB; CETUXIMAB; DEFOROLIMUS; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LONAFARNIB; MATUZUMAB; MOTESANIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PANITUMUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ADVANCED CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG TARGETING; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOTYPE PHENOTYPE CORRELATION; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 77954495172     PISSN: 18759181     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.path.2010.04.001     Document Type: Review

References (68)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
2. Hampton T. Lung cancer trials probe effects of maintenance therapy, targeted agents. JAMA 2009, 302(6):616-618.
3. Sato M., Shames D.S., Gazdar A.F., et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007, 2(4):327-343.
4. Winer E., Gralow J., Diller L., et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2009, 27(5):812-826.
5. Ellis L.M., Hicklin D.J. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009, 15(24):7471-7478.
6. Ding L., Getz G., Wheeler D., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455(7216):1069-1075.
7. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359(13):1367-1380.
8. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22(5):777-784.
9. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
10. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496):1527-1537.
11. Lynch T.J., Bell D., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
12. Paez J.G., Janne P., Lee J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
13. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
14. Sharma S.V., Bell D., Settleman J., et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7(3):169-181.
15. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13(17):4954-4955.
16. Pratilas C.A., Hanrahan A., Halilovic E., et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008, 68(22):9375-9383.
17. Linardou H., Dahabreh I., Bafaloukos D., et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009, 6(6):352-366.
18. Ahrendt S.A., Decker P.A., Alawi E.A., et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001, 92(6):1525-1530.
19. Eberhard D.A., Johnson B., Amler L., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23(25):5900-5909.
20. Riely G.J., Kris M., Rosenbaum D., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14(18):5731-5734.
21. Pao W., Miller V., Politi K., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
22. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
23. Sequist L.V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007, 12(3):325-330.
24. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008, 15(4):241-247.
25. Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol 2006, 1:19.
26. Dacic S., Shuai Y., Yousem S., et al. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010, 23(2):159-168.
27. Hirsch F.R., Herbst R.S., Olsen C., et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008, 26(20):3351-3357.
28. Sholl L.M., John lafrate A., Chou Y., et al. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 2007, 20(10):1028-1035.
29. Clark G.M., Zborowski D.M., Culbertson J.L., et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 2006, 1(8):837-846.
30. Hirsch F.R., Dziaddziuszko R., Thatcher N., et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008, 112(5):1114-1121.
31. Jeon Y.K., Sung S.W., Chung J.H., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006, 54(3):387-398.
32. Brevet M., Arcila M., Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010, 12(2):169-176.
33. Yu J., Kane S., Wu J., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15(9):3023-3028.
34. Jackman D.M., Yeap B., Sequist L., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12(13):3908-3914.
35. Sasaki H., Shimizu S., Endo K., et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006, 118(1):180-184.
36. Cappuzzo F., Hirsch F., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97(9):643-655.
37. Hirsch F.R., Varella-Garcia M., McCoy J., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005, 23(28):6838-6845.
38. Mok T.S.K., Wu Y.L., Yu C.J., et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(30):5080-5087.
39. Zhu C.Q., da Cunha Santos G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26(26):4268-4275.
40. Cappuzzo F., Janne P.A., Skokan M., et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009, 20(2):298-304.
41. Tang Z., Du R., Jiang S., et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008, 99(6):911-922.
42. Miller V.A., Kris M.G., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22(6):1103-1109.
43. Miller V.A., Riely G.J., Zakowski M.F., et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26(9):1472-1478.
44. West H.L., Franklin W.A., McCoy J., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006, 24(12):1807-1813.
45. Marks J.L., Broderick S., Zhou Q., et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008, 3(2):111-116.
46. Motoi N., Szoke J., Riely G.J., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32(6):810-827.
47. Ninomiya H., Hiramatsu M., Inamura K., et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas: significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 2009, 63(2):235-240.
48. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346.
49. Zakowski M.F., Hussain S., Pao W., et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 2009, 133(3):470-477.
50. Finberg K.E., Sequist L., Joshi V., et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007, 9(3):320-326.
51. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
52. West H., Harpole D., Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 2009, 136(4):1112-1118.
53. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):2184-2191.
54. Lamant L., Megetto F., al Saati T., et al. High incidence of the t (2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996, 87(1):284-291.
55. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263(5151):1281-1284.
56. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131(6):1190-1203.
57. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
58. Koivunen J.P., Mermel C., Zejnullahu K., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14(13):4275-4283.
59. Soda M., Takada S., Takeuchi K., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008, 105(50):19893-19897.
60. Shaw A.T., Yeap B.W., Mino-kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
61. Rodig S.J., Mino-Kenudson M., Dacic S., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16):5216-5223.
62. Inamura K., Takeuchi K., Togashi Y., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22(4):508-515.
63. Mino-Kenudson M., Chirieac L.R., Law K., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16(5):1561-1571.
64. Shigematsu H., Takahashi T., Nomura M., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005, 65(5):1642-1646.
65. Stephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431(7008):525-526.
66. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 2002, 21(45):6970-6981.
67. Heist R.S., Zhou W., Chirieac L.R., et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007, 25(16):2243-2247.
68. Azzoli C.G., Krug L.M., Miller V.A., et al. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol 2002, 29(1 Suppl 4):59-65.